Nxera Pharma Spins Out GPCR Program, Secures $275M Milestone Deal
Event summary
- Nxera Pharma out-licensed a GPCR-targeted program to a new company (NewCo), retaining rights to Japan and Asia-Pacific territories.
- The deal includes up to $275M in milestone payments and tiered royalties, with Nxera holding a significant minority equity stake in NewCo.
- Nxera participated in NewCo’s Series A financing, co-founded with a syndicate of healthcare and life sciences investors.
- The spin-out model follows Orexia Therapeutics/Centessa Pharmaceuticals, which was acquired by Lilly for up to $7.8B.
- Dr. Patrik Foerch, Nxera’s Chief Scientific Officer, joined NewCo’s Board of Directors to oversee development.
The big picture
Nxera Pharma’s spin-out model aligns with broader industry trends of biotech companies monetizing non-core assets through strategic partnerships. The deal mirrors the Orexia Therapeutics/Centessa Pharmaceuticals acquisition by Lilly, highlighting the value of GPCR-targeted programs. By retaining equity and milestone payments, Nxera positions itself to benefit from potential upside while reducing development risk.
What we're watching
- Execution Risk
- Whether NewCo can accelerate preclinical studies and advance the program toward global clinical trials as planned.
- Valuation Dynamics
- The pace at which Nxera’s equity stake in NewCo appreciates, given the potential for up to $275M in milestone payments.
- Market Expansion
- How Nxera leverages retained rights in Japan and Asia-Pacific to commercialize the program if development succeeds.